Merck licenses a KRAS G12D inhibitor for $400M upfront
Merck has entered a multi-billion dollar agreement with China's SciBrunch Therapeutics to develop a preclinical KRAS G12D inhibitor.
9 trends tracked about this subject — the full history, oldest to newest below.
Merck has entered a multi-billion dollar agreement with China's SciBrunch Therapeutics to develop a preclinical KRAS G12D inhibitor.
Recent studies detail an mRNA immunotherapy strategy that reportedly leads to pancreatic cancer disappearing in mice.
7 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
10 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
A mutant KRAS vaccine yields early positive results in its first human clinical trial for high-risk pancreatic cancer patients.
A Johns Hopkins-developed KRAS vaccine has demonstrated safety and durable immune responses in a trial focused on preventing pancreatic cancer in high-risk individuals.
A new pill-based treatment targeting KRAS-mutated pancreatic cancer is generating expert excitement and hope for patient longevity.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.